Spots Global Cancer Trial Database for Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer

Official Title: A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer

Study ID: NCT00002928

Conditions

Ovarian Cancer

Interventions

paclitaxel

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or progressive advanced epithelial ovarian cancer following previous paclitaxel.

Detailed Description: OBJECTIVES: I. Evaluate the activity of paclitaxel when administered on a weekly schedule to patients with advanced ovarian cancer who have failed paclitaxel on a 3 or 24 hour infusion schedule. II. Evaluate the toxic effects of paclitaxel when administered on a weekly schedule in this patient population. III. Correlate response with quality of life outcomes, including symptom distress, performance status, and global quality of life. OUTLINE: This is a single center, open label study. Paclitaxel is administered intravenously every week as a 1 hour infusion. Patients receive prophylactic anti-allergy premedication prior to paclitaxel. PROJECTED ACCRUAL: 25-30 patients accrued per year.